Search

Objective To investigate the clinical efficacy and safety of long-term application of omalizumab in the treatment of severe hormone dependent allergic asthma. Methods Seven cases of severe hormone dependent allergic asthma treated with omalizumab for 3 years were collected from Department of Respiratory Medicine, Zhongshan Hospital, Fudan University. Results of oral corticosteroid (OCS) doses, acute attack frequency, asthma control test (ACT), asthma quality of life (AQLQ), forced vital capacity (FVC), forced expiratory volume in first second (FEV1) and percentage to predicted value (FEV1% pred), and forced expiratory volume in the first second over forced vital capacity (FEV1/FVC) before and after omalizumab treatment were compared in this study. Results After treatment of omalizumab for 3 years, the oral prednisone doses of the 7 cases decreased from 15.0 (15.0-22.5) mg/d to 2.5（0-10.0) mg/d (P<0.01), and acute attack frequency decreased from 6 (4-7) per year to 0（0-1) per year (P<0.01). The ACT scores of 7 patients with severe asthma increased from 18.0 (13.0-20.0) to 22.0 (18.0-24.0), and AQLQ scores increased from (4.5±1.4) to (5.1±1.1). After treatment of omalizumab for 3 years, FEV1 increased from baseline (2.2±1.0) L to (2.5±1.3) L, FEV1% pred increased from baseline 74.4%±29.2% to 77.5%±27.2%, FEV1/FVC (%) increased from baseline 68.4%±11.9% to 69.8%±16.3%. One case had swelling at the injection site, and the rest had no obvious adverse reactions during the long-term treatment with omalizumab. Conclusion Long-term application of omalizumab in the treatment of severe hormone dependent allergic asthma could effectively reduce oral prednisone doses and acute attack frequency, control asthma symptoms and improve pulmonary ventilation function of patients and also has good safety. [ABSTRACT FROM AUTHOR]

Objective To quantify the degree of pulmonary cystic damage in CT and compare its correlation with pulmonary function tests（PFTs）and serum levels of vascular endothelial growth factor （VEGF-D），and to study the potential of quantitative CT to assess the degree of lung damage and decide treatment in lymphangioleiomyomatosis（LAM）. Methods Pulmonary cystic areas in CT images were identified by the artificial intelligence software.The volumetric percentage of cystic regions of the total lung volume was calculated to get a cyst score.The association between the 36 times of CT scan and PFTs were analyzed in 21 patients. The correlation of serum VEGF-D levels of 17 patients and their 24 times of CT scan were studied.A ROC curve was calculated to select the threshold at which the cyst scores could predict the lung impairment best. Results Cyst scores correlated significantly with percentage of predicted forced of expiratory volume in one second （FEV1%pred）（r=-0.72，P<0.001） and percentage of predicted diffusion capacity（DLCO/VA%pred）（r=-0.821，P<0.000 1），while its correlation with serum VEGF-D levels（r=-0.143，P=0.506）was not obvious. The Youden index is max（0.667）with a 94.44% sensitivity and a 72.22% specificity when cyst score is 15.80%. Conclusion Pulmonary cyst scores on CT is strongly correlated with FEV1%pred and DLCO/VA% pred. However，the association with serum levels of VEGF-D is not obvious. Cyst score>15.80% might indicate an abnormal lung function and patients are recommended a sirolimus treatment. [ABSTRACT FROM AUTHOR]

Objective To analyze the consistency of pulmonary function parameters measured by portable and Jaeger spirometer and explore the clinical feasibility of the portable spirometer. Methods The pulmonary ventilation functions of 151 subjects were simultaneously measuerd by Jaeger spirometer and Medikro PRO portable spirometer. Eight parameters.i. e. .forced vital capacity (FVC), forced expiratory volume in one second (FEV, ), precentage of predicted forced expiratory volume in one second (FEV, J'cpred)

Objective To observe surgical safety for patients whose pulmonary functions manifest were obstructive ventilatory dysfunction. Methods The data of totally 122 patients with obstructive ventilatory dysfunction in their perioperative period, such as hospital stays, hospital costs, treatment methods and postoperative pulmonary adverse events, had been collected and analyzed. The influnce of different airway medications and different grades of obstructive ventilatory dysfunction on the above date were compared. Results According to the result of regression analysis, airway management medication had a highly significant negative correlation with postoperative pulmonary adverse events (b=-0.807, P<0.001) and hospital stays (b=-1.906, P=0.003), and adverse events decreased significantly if the patients were medicated in their airways before and after surgery compared with neither before or after surgery (P=0.013). There was no significant difference in the 4 study endpoints (postoperative pulmonary adverse events, hospital stays, ICU stays, hospital costs) among different groups of obstructive ventilatory dysfunction (P=0.240, 0.755, 0.360, 0.320), and the patients with severe obstructive ventilatory dysfunction were medicated more actively. While different groups of surgical type had significant difference of the 4 study endpoints (P all <0.001). Conclusions Airway management medication is the most essential factor of surgical safety for patients with obstructive ventilatory dysfunction. Even though preoperative pulmonary function manifests as severe obstructive ventilatory dysfunction, patients can go through the operation safely by effective airway management. [ABSTRACT FROM AUTHOR]